Search research articles
Contact Us
Filters
Showing results (41-50 of 112) with videos related to
Page
of 12
Sort By:
Digestive Diseases (Basel, Switzerland)
|
November 4, 2000
Pathophysiology and pharmacological treatment of gastroesophageal reflux disease
M Storr, A Meining, H D Allescher
Neurogastroenterology and Motility
|
May 2, 2015
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases
A Jarmuż, M Zielińska, M Storr, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
March 19, 2018
Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease
H Zatorski, P Mosinska, M Storr, et al.
Endoscopy
|
May 19, 2011
Duodenal vascular ectasia (DUVE) associated with hematopoietic stem cell transplant
S E Congly, Z H Gao, M Storr
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
May 13, 2010
Botulinum toxin in the treatment of diffuse esophageal spasm
M Bashashati, C Andrews, S Ghosh, et al.
Neurogastroenterology and Motility
|
August 27, 2016
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease
C Hasenoehrl, U Taschler, M Storr, et al.
Deutsche Medizinische Wochenschrift (1946)
|
April 29, 1998
[Polyposis of the gastrointestinal tract as a manifestation of diffuse follicular lymphatic hyperplasia]
M Storr, N Weigert, C Fellbaum, et al.
Life Sciences
|
June 5, 2002
Endomorphins 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastric fundus
M Storr, E Gaffal, V Schusdziarra, et al.
Neurogastroenterology and Motility
|
May 23, 2013
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
J Fichna, A Sibaev, M Sałaga, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
April 26, 2019
The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome
A Szymaszkiewicz, A Malkiewicz, M Storr, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 112) with videos related to
Sort By:
Page
of 12
Digestive Diseases (Basel, Switzerland)
|
November 4, 2000
Pathophysiology and pharmacological treatment of gastroesophageal reflux disease
M Storr, A Meining, H D Allescher
Neurogastroenterology and Motility
|
May 2, 2015
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases
A Jarmuż, M Zielińska, M Storr, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
March 19, 2018
Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease
H Zatorski, P Mosinska, M Storr, et al.
Endoscopy
|
May 19, 2011
Duodenal vascular ectasia (DUVE) associated with hematopoietic stem cell transplant
S E Congly, Z H Gao, M Storr
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
May 13, 2010
Botulinum toxin in the treatment of diffuse esophageal spasm
M Bashashati, C Andrews, S Ghosh, et al.
Neurogastroenterology and Motility
|
August 27, 2016
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease
C Hasenoehrl, U Taschler, M Storr, et al.
Deutsche Medizinische Wochenschrift (1946)
|
April 29, 1998
[Polyposis of the gastrointestinal tract as a manifestation of diffuse follicular lymphatic hyperplasia]
M Storr, N Weigert, C Fellbaum, et al.
Life Sciences
|
June 5, 2002
Endomorphins 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastric fundus
M Storr, E Gaffal, V Schusdziarra, et al.
Neurogastroenterology and Motility
|
May 23, 2013
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
J Fichna, A Sibaev, M Sałaga, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
April 26, 2019
The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome
A Szymaszkiewicz, A Malkiewicz, M Storr, et al.
Page
of 12